跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
周 俊良
主治醫師
,
臺北醫學大學附設醫院
成員
,
臺北醫學大學胸腔醫學研究中心
https://orcid.org/0000-0002-8061-703X
電子郵件
drchou1024
gmail
com
h-index
1174
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1999
2024
每年研究成果
概覽
指紋
網路
研究成果
(45)
類似的個人檔案
(7)
指紋
查看啟用 Chun-liang Chou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Self-Expandable Metallic Stent
98%
COVID-19
74%
Bronchoscopy
71%
Cryotherapy
62%
Odds Ratio
61%
Stenting
57%
Stent Fracture
55%
Asthma
53%
Acute Respiratory Failure
52%
Erlotinib
49%
Cohort Analysis
49%
Neutrophil
49%
Bronchoscope
49%
Airway Obstruction
47%
Biopsy
44%
Granulation Tissue
42%
Intensive Care Unit
39%
Cancer
33%
Neoplasm
31%
Gefitinib
30%
Non Small Cell Lung Cancer
29%
Diagnosis
29%
Infection
29%
Cystic Fibrosis
28%
Lung Biopsy
28%
Acute Lung Injury
27%
Small Cell Lung Cancer
26%
Lung Adenocarcinoma
26%
Randomized Controlled Trial
26%
Disease
25%
Fistula
24%
Mucosa
24%
Lung Cancer
24%
Recurrent Disease
24%
Recanalization
24%
Endobronchial Ultrasonography
24%
Idiopathic Interstitial Pneumonia
24%
Rapamycin
24%
Esophageal Cancer
24%
Bronchiectasis
24%
Epidermal Growth Factor Receptor
24%
Debulking
24%
Interstitial Collagenase
24%
Thromboembolism
24%
Elastase
24%
Fluoroscopy
24%
Pleurisy
24%
Cell Proliferation
24%
Immune Dysregulation
24%
Chemokine
24%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
80%
Non Small Cell Lung Cancer
77%
Disease
55%
Acute Respiratory Failure
52%
Coronavirinae
49%
Erlotinib
49%
Immunoglobulin E
49%
Epidermal Growth Factor Receptor
49%
Oxidizing Agent
49%
Neoplasm
36%
Epidermal Growth Factor Receptor Kinase Inhibitor
31%
Gefitinib
30%
Lipocortin 5
28%
Acute Lung Injury
27%
Randomized Controlled Trial
26%
Chemotherapy
26%
Elastase
24%
Absence
24%
Thromboembolism
24%
Influenza A Virus (H1N1)
24%
Lung Cancer
24%
Mitogen Activated Protein Kinase
24%
Cytoprotective Agent
24%
Multiple Organ Failure
24%
Leukocyte Elastase
24%
Interstitial Pneumonia
24%
Mammalian Target of Rapamycin Inhibitor
24%
Tumor Necrosis Factor
24%
Peripheral Lung Lesion
24%
Allergic Asthma
24%
B Cell Lymphoma
24%
Lung Adenocarcinoma
24%
Caspase
24%
Rapamycin
24%
Respiratory Failure
24%
Immune Dysregulation
24%
Restenosis
24%
Calpain
24%
Interleukin 5
24%
Omalizumab
24%
Ciclesonide
24%
Sepsis
24%
Ropeginterferon Alpha2b
24%
Budesonide
24%
Inflammation
21%
Interleukin 13
20%
Cyclin D1
19%
Flow Cytometry
17%
Cytokine
14%
Arginase
14%
Immunology and Microbiology
Asthma
100%
Immunoglobulin E
49%
Upregulation
49%
COVID-19
49%
B Cell
44%
Normal Human
43%
Cytokine
42%
Interleukin 5
34%
Computer Assisted Tomography
32%
Interleukin-5 Receptor
30%
CD14
29%
Pulmonary Inflammation
29%
Neutrophil
29%
Neutrophil Granulocyte
27%
Cell Death
27%
Bcl-2
24%
Immune Dysregulation
24%
Cross Linking
24%
Ciclesonide
24%
Defensin
24%
Chemotaxis
24%
Allergic Asthma
24%
Eosinophil Granulocyte
24%
Omalizumab
24%
Myeloid-Derived Suppressor Cell
24%
CD34
24%
Budesonide
24%
Severe Acute Respiratory Syndrome
24%
Chemokine
24%
Oxidative Stress
24%
Ropeginterferon Alpha2b
24%
Cell Activation
24%
Interleukin 33
24%
Mast Cell
24%
Monocyte
21%
Interleukin 13
20%
T Cell
18%
Interleukin-33
17%
CD19
14%
Blood Plasma
13%
T-Helper Cell
12%
Dilatation
12%
Bronchoalveolar Lavage Fluid
12%
Allele
12%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
CXCR4
10%
Alpha Chain
10%
CD16
9%
CD4
9%
Plasmablast
9%
